ABSTRACT

Introduction: The increased risk of hemolytic reactions and erythrocyte recovery delay in ABO incompatible hematopoietic stem cell transplantation (HSCT) are well established. Effects of ABO incompatibility on other transplantation outcomes are evaluated in this study.

Subjects and Methods: We prospectively followed 501 patients undergoing allogeneic stem cell transplantation regarding their ABO compatibility groups for a median time of 34.7 months. Patients were studied in minor, major and bidirectional mismatched and matched groups.

Result: Mean survival time (OS) was lower in minor mismatched group (p-value = 0.017). Minor and bidirectional mismatched groups received significantly more packed cell units than matched group (p-value < 0.0001 and p-value = 0.002, respectively). Mean number of platelet unit infusion was significantly more in major mismatched recipients than matched group (p-value = 0.031). Death rate was much more than expected in minor mismatched group. Two cases of PRCA (pure red cell aplasia) were found in major mismatched group. No statistically significant difference was found in the incidence of acute GVHD, chronic GVHD, time to neutrophil recovery, relapse-free survival, non-relapse mortality and relapse rate among groups.

Conclusion: In order to prevent complications of ABO-incompatible SCT such as decrease in OS and the need for more transfusions, choosing ABO-compatible donors would improve transplantation outcomes.

Keywords: ABO incompatibility, Allogeneic hematopoietic stem cell transplantation
issue during recent years. If ABO incompatibility deteriorates graft outcomes, choosing the better donor may improve HSCT results, albeit if possible.

SUBJECTS AND METHODS

We prospectively followed the patients (n=501) undergoing allogeneic stem cell transplantation between 2010 and 2012 in our center for a median time of 34.7 months. Patients' characteristics are shown in Table1.

<table>
<thead>
<tr>
<th>Table1: Patients' characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>Recipient age</td>
</tr>
<tr>
<td>Mean (Median)</td>
</tr>
<tr>
<td>Range</td>
</tr>
<tr>
<td>Recipient gender</td>
</tr>
<tr>
<td>Male</td>
</tr>
<tr>
<td>Female</td>
</tr>
<tr>
<td>Gender mismatch</td>
</tr>
<tr>
<td>D-R Sex-Match</td>
</tr>
<tr>
<td>Female to Male</td>
</tr>
<tr>
<td>Male to Female</td>
</tr>
<tr>
<td>Conditioning regimen</td>
</tr>
<tr>
<td>Myeloablative</td>
</tr>
<tr>
<td>Non-myeloablative</td>
</tr>
<tr>
<td>ATG in Conditioning</td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>HLA type</td>
</tr>
<tr>
<td>Full match sibling</td>
</tr>
<tr>
<td>HLA matched other relative</td>
</tr>
<tr>
<td>HLA mismatch relative</td>
</tr>
<tr>
<td>Primary diseases</td>
</tr>
<tr>
<td>Malignant</td>
</tr>
<tr>
<td>Benign</td>
</tr>
<tr>
<td>Stem cell source</td>
</tr>
<tr>
<td>PBSC</td>
</tr>
<tr>
<td>BM</td>
</tr>
<tr>
<td>CB</td>
</tr>
<tr>
<td>Mononuclear Cell Dose*10^8/Kg</td>
</tr>
<tr>
<td>Mean (Median)</td>
</tr>
<tr>
<td>CD34 cell dose*10^8/Kg</td>
</tr>
<tr>
<td>Mean (Median)</td>
</tr>
<tr>
<td>CD3 cell dose*10^8/Kg</td>
</tr>
<tr>
<td>Mean (Median)</td>
</tr>
</tbody>
</table>

PBSC: peripheral Blood Stem Cell, BM: Bone Marrow, CB: Cord Blood.

Malignant diseases (n=318) included acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), malignant lymphoma and multiple myeloma (MM), while severe aplastic anemia (SAA), thalassemia, Fanconi anemia, osteopetrosis and leukocyteadhesion deficiency syndrome were defined as benign disorders (n=183). Four hundred forty-two patients received myeloablative (MA) conditioning regimen and others (n=59) were transplanted with non-myeloablative regimen.

Stem cell source was peripheral blood in 456 patients and the rest received cells from bone marrow (n=38) and cord blood (n=7). Acute GVHD (aGVHD) grade was determined according to...
Glucksberg system by presentation and staging of gastrointestinal, liver and skin GVHD at least seven days after transplantation.\(^9\) Absolute neutrophil count (ANC) more than 0.5 *10^9/L for 3 consequent days was considered as neutrophil recovery and platelet engraftment was determined by platelet count of greater than 20*10^9/L for three consequent days without any supplementary platelet. Chimerism was assessed on days +15, +30, +60 and +90. Relapse and secondary graft failure were identified by clinical and/or hematologic recurrence or chimerism decline. Death due to treatment except relapse was defined as none-relapse mortality (NRM). Dates of relapse and death were recorded to identify relapse-free survival (RFS) and overall survival (OS). All participants signed the informed consent forms.

**Statistical Analysis**

Statistical analysis was performed using SPSS version 22.0. The incidences of death, relapse, acute and chronic GVHD were compared in each ABO blood group incompatibility using cross-tab tables with likelihood-ratio \( \chi^2 \) statistics. The means of recipient’s and donor’s age, platelet and WBC engraftment, packed cell and platelet infusion were compared using ANOVA and Kruskal-Wallis with post-hoc statistics. Overall survival and relapse-free survival were analyzed by the Kaplan-Meier method, and the Breslow test was used to examine significant differences among blood group compatibilities. Factors that significantly affected survival and relapse-free survival were evaluated by the Cox proportional hazards multivariate model. Logistic regression multivariate analysis was used to determine significant effects of variables on incidence of mortality, relapse, and non-relapse mortality, acute and chronic GVHD as outcomes.\(^10,12\)

**RESULTS**

According to ABO compatibility of donors and recipients, four groups were distinguished: match, major mismatch, minor mismatch and bidirectional ABO mismatch. Recipient’s gender, gender mismatch, conditioning regimen, HLA matching, primary disease, stem cell source, receiving ATG(anti-thymocyte globulin) in conditioning regimen, mononuclear cells, CD34 and CD3 cell doses were almost equally distributed in these four groups. Only recipient’s age was different among groups (p-value= 0.034). Table 1 shows univariate analysis of patients’ characteristics. Univariate analysis of transplantation outcomes regarding BO compatibility groups showed no significant difference in aGVHD, cGVHD, time to neutrophil recovery, NRM and relapse rate in all groups. Chimerism was different among groups, but it was not significant (p-value=0.078). Mean days of platelet engraftment, units of packed cell transfusion, units of platelet infusion and death incidence rate were statistically different (Table 2). Minor and bidirectional mismatched groups received significantly more packed cells than matched group (p-value<0.0001 and p-value =0.002, respectively). Although major mismatched patients received more packed cells than matched group, the difference was not significant (p value =0.06). The Mean number of platelet units transfused was significantly more in major mismatched recipients than matched group (p-value=0.031). Death rate was less than expected in matched group and it was much more than expected in minor mismatched group (Table 2).

Totally, overall survival was 39.8 months (95% CI: 38.1 – 41.5). In univariate analysis, mean survival time (OS) was statistically different among groups (p-value= 0.017) and the worst result was found in minor mismatched one. Relapse-free survival (RFS) was 45.3 (95% CI: 44.0 – 46.7) in all patients and it was lower in minor mismatched group, but the difference was not statistically significant (p value=0.30)

In multivariate analysis of overall survival, minor mismatch ABO incompatibility decreased survival (RR: 2.29, CI: 1.47-3.55, p-value=0.0001). Other ABO incompatibilities did not affect survival (Table 3, Figure 1-A). Malignant diseases decreased OS (RR:2.62,CI:1.66-4.14,p-value<0.0001). Grade II to IV acute GVHD, both GI and liver deteriorated the outcome(RR:1.80,CI:1.26-2.57,p-value=0.001 and RR:2.70,CI:1.18-6.17,p-value=0.018,respectively),while limited cGVHD improved OS(RR: 0.48,CI: 0.29-0.81, p value=0.006)(Table 3).
Table 2: Post-transplantation outcomes by ABO incompatibility

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>Match</th>
<th>Major mismatch</th>
<th>Minor mismatch</th>
<th>Bidirectional</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGVHD Grade ≥ II</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>212</td>
<td>112</td>
<td>47</td>
<td>37</td>
<td>16</td>
<td>0.190</td>
</tr>
<tr>
<td>No</td>
<td>274</td>
<td>171</td>
<td>49</td>
<td>40</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>CGVHD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>189</td>
<td>105</td>
<td>37</td>
<td>32</td>
<td>15</td>
<td>0.46</td>
</tr>
<tr>
<td>No</td>
<td>312</td>
<td>186</td>
<td>64</td>
<td>47</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>Chimerism</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 95%</td>
<td>442</td>
<td>257</td>
<td>92</td>
<td>64</td>
<td>29</td>
<td>0.078</td>
</tr>
<tr>
<td>&lt; 95%</td>
<td>59</td>
<td>34</td>
<td>9</td>
<td>15</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Neutrophil recovery (+Days)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean</td>
<td>14.02</td>
<td>13.59</td>
<td>14.98</td>
<td>13.95</td>
<td>15.23</td>
<td>0.64</td>
</tr>
<tr>
<td>(Median)</td>
<td>(13)</td>
<td>(13)</td>
<td>(13)</td>
<td>(13)</td>
<td>(13)</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>1-66</td>
<td>3-27</td>
<td>9-66</td>
<td>8-44</td>
<td>1-51</td>
<td></td>
</tr>
<tr>
<td>Packed Cell infusion (Unit)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Mean</td>
<td>17.97</td>
<td>17.15</td>
<td>19.78</td>
<td>18.66</td>
<td>18.07</td>
<td>0.04</td>
</tr>
<tr>
<td>(Median)</td>
<td>(16)</td>
<td>(15)</td>
<td>(17)</td>
<td>(16)</td>
<td>(15)</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>4-101</td>
<td>4-101</td>
<td>10-71</td>
<td>8-69</td>
<td>10-38</td>
<td></td>
</tr>
<tr>
<td>Platelet infusion (Unit)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.002</td>
</tr>
<tr>
<td>Mean</td>
<td>4.42</td>
<td>3.51</td>
<td>6.18</td>
<td>5.18</td>
<td>5.43</td>
<td></td>
</tr>
<tr>
<td>(Median)</td>
<td>(2)</td>
<td>(2)</td>
<td>(2)</td>
<td>(2)</td>
<td>(3)</td>
<td></td>
</tr>
<tr>
<td>Relapse¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>75</td>
<td>44</td>
<td>12</td>
<td>16</td>
<td>3</td>
<td>0.38</td>
</tr>
<tr>
<td>No</td>
<td>426</td>
<td>247</td>
<td>89</td>
<td>63</td>
<td>27</td>
<td></td>
</tr>
<tr>
<td>Death¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>139</td>
<td>68</td>
<td>30</td>
<td>31</td>
<td>10</td>
<td>0.034</td>
</tr>
<tr>
<td>No</td>
<td>362</td>
<td>223</td>
<td>71</td>
<td>48</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>Non-Relapse Mortality</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NRM</td>
<td>73</td>
<td>32</td>
<td>18</td>
<td>15</td>
<td>8</td>
<td>0.193</td>
</tr>
<tr>
<td>RM</td>
<td>66</td>
<td>36</td>
<td>12</td>
<td>16</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

¹Median follow-up: 34.72 months (33.26 – 36.18)

Figure 1-A: Overall Survival by ABO incompatibility Groups in multivariate Cox regression analysis
Table 3: Multivariate analysis for overall survival and relapse-free survival

<table>
<thead>
<tr>
<th>Factors</th>
<th>Overall Survival</th>
<th></th>
<th>Relapse-Free Survival</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Relative Risk (95% CI)</td>
<td>P value</td>
<td>Relative Risk (95% CI)</td>
<td>P value</td>
</tr>
<tr>
<td>ABO compatibility</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Match</td>
<td>1.0</td>
<td></td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Major mismatch</td>
<td>1.24 (0.77-1.99)</td>
<td>0.38</td>
<td>0.84 (0.42-1.67)</td>
<td>0.61</td>
</tr>
<tr>
<td>Minor mismatch</td>
<td>2.29 (1.47-3.55)</td>
<td>&lt;0.0001</td>
<td>1.78 (0.98-3.26)</td>
<td>0.59</td>
</tr>
<tr>
<td>Bidirectional</td>
<td>1.37 (0.65-2.88)</td>
<td>0.41</td>
<td>0.87 (0.26-2.93)</td>
<td>0.82</td>
</tr>
<tr>
<td>ATG</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1.0</td>
<td></td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>0.81 (0.68-3.08)</td>
<td>0.63</td>
<td>0.31 (0.03-3.04)</td>
<td>0.31</td>
</tr>
<tr>
<td>Primary Disorder</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benign</td>
<td>1.0</td>
<td></td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Malignant</td>
<td>2.62 (1.66-4.14)</td>
<td>&lt;0.0001</td>
<td>20.5 (6.3-66.9)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Recipient Age</td>
<td>1.007 (0.988-1.027)</td>
<td>0.45</td>
<td>1.001 (0.975-1.027)</td>
<td>0.96</td>
</tr>
<tr>
<td>Donor Age</td>
<td>0.998 (0.979-1.017)</td>
<td>0.81</td>
<td>0.971 (0.953-0.989)</td>
<td>0.002</td>
</tr>
<tr>
<td>AGVHD Grade ≥II</td>
<td>0.40 (0.14-1.12)</td>
<td>0.08</td>
<td>0.77 (0.14-4.21)</td>
<td>0.76</td>
</tr>
<tr>
<td>Skin</td>
<td>0.63 (0.18-2.19)</td>
<td>0.47</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Gl</td>
<td>1.80 (1.26-2.57)</td>
<td>0.001</td>
<td>1.52 (0.28-8.11)</td>
<td>0.62</td>
</tr>
<tr>
<td>Liver</td>
<td>2.70 (1.18-6.17)</td>
<td>0.018</td>
<td>0.78 (0.16-3.83)</td>
<td>0.76</td>
</tr>
<tr>
<td>Chronic GVHD</td>
<td>0.77 (0.48-1.25)</td>
<td>0.29</td>
<td>0.53 (0.31-0.89)</td>
<td>0.02</td>
</tr>
<tr>
<td>No</td>
<td>1.0</td>
<td></td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Limited</td>
<td>0.48 (0.29-0.81)</td>
<td>0.006</td>
<td>0.73 (0.40-1.33)</td>
<td>0.30</td>
</tr>
<tr>
<td>Extensive</td>
<td>0.94 (0.60-1.47)</td>
<td>0.79</td>
<td>0.23 (0.09-0.63)</td>
<td>0.004</td>
</tr>
<tr>
<td>CD34 Cell dose</td>
<td>1.010 (0.925-1.103)</td>
<td>0.82</td>
<td>1.123 (0.995-1.267)</td>
<td>0.06</td>
</tr>
<tr>
<td>Conditioning Regimen</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-MA</td>
<td>1.0</td>
<td></td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>MA</td>
<td>1.67 (0.85-3.26)</td>
<td>0.13</td>
<td>2.41 (0.74-7.87)</td>
<td>0.14</td>
</tr>
<tr>
<td>Gender Mismatch</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D-R Sex-Match</td>
<td>1.0</td>
<td></td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Female to Male</td>
<td>1.42 (0.93-2.19)</td>
<td>0.10</td>
<td>1.30 (0.72-2.34)</td>
<td>0.37</td>
</tr>
<tr>
<td>Male to Female</td>
<td>1.13 (0.70-1.79)</td>
<td>0.61</td>
<td>0.84 (0.44-1.59)</td>
<td>0.59</td>
</tr>
<tr>
<td>HLA Matching</td>
<td>1.0</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Match other relative</td>
<td>2.05 (0.64-6.59)</td>
<td>0.23</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Mismatch relative</td>
<td>1.46 (0.31-6.74)</td>
<td>0.62</td>
<td>8.12 (0.84-78.4)</td>
<td>0.07</td>
</tr>
<tr>
<td>ANC recovery</td>
<td>1.030 (0.983-1.079)</td>
<td>0.21</td>
<td>1.057 (0.95-1.175)</td>
<td>0.31</td>
</tr>
<tr>
<td>Plt recovery</td>
<td>0.995 (0.964-1.026)</td>
<td>0.73</td>
<td>0.985 (0.938-1.033)</td>
<td>0.52</td>
</tr>
</tbody>
</table>

Table 3 also includes Cox regression multivariate analysis results for RFS. ABO incompatibility was not correlated with RFS (Figure 1-B). Malignant disease decreased RFS (RR: 20.5, CI: 6.3-66.9, p-value<0.0001). In contrast, donor’s age and extensive cGVHD improved RFS (RR: 0.971, CI: 0.953-0.989, p-value=0.002 and RR: 0.23, CI: 0.09-0.63, p-value=0.004, respectively).

The cumulative incidence of relapse was not significantly different among the four groups (Figure 1-C). Malignant primary disorder increased relapse rate (RR:31.39, CI: 8.33-118.26, p-value<0.0001).
Extensive cGVHD and donor’s age decreased relapse rate (RR: 0.24, CI: 0.09-0.65, p-value=0.005 and RR: 0.970, CI: 0.950-0.991, p-value=0.005, respectively). Donation from a mismatched relative was a risk factor for relapse (RR: 12.39, CI: 1.10-140.32, p-value=0.04) (Table 4).

Table 4: multivariate analysis for Relapse and Non-Relapse Mortality

<table>
<thead>
<tr>
<th>Factors</th>
<th>Relapse</th>
<th>Non-Relapse Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Relative Risk (95% CI)</td>
<td>P value</td>
</tr>
<tr>
<td></td>
<td>Relative Risk (95% CI)</td>
<td>P value</td>
</tr>
<tr>
<td>ABO compatibility</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Match</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Major mismatch</td>
<td>0.71 (0.31-1.60)</td>
<td>0.41</td>
</tr>
<tr>
<td>Minor mismatch</td>
<td>1.47 (0.67-3.22)</td>
<td>0.33</td>
</tr>
<tr>
<td>Bidirectional</td>
<td>0.80 (0.20-3.20)</td>
<td>0.75</td>
</tr>
<tr>
<td>ATG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>No</td>
<td>0.24 (0.02-3.60)</td>
<td>0.30</td>
</tr>
<tr>
<td>Primary Disorder</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benign</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Malignant</td>
<td>31.39 (8.33-118.26)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Recipient Age</td>
<td>1.001 (0.970-1.033)</td>
<td>0.96</td>
</tr>
<tr>
<td>Donor Age</td>
<td>0.970 (0.950-0.991)</td>
<td>0.005</td>
</tr>
<tr>
<td>AGVHD Grade ≥ II</td>
<td>0.68 (0.11-4.33)</td>
<td>0.69</td>
</tr>
<tr>
<td>Skin</td>
<td>N/A</td>
<td>1.02 (1.005-1.044)</td>
</tr>
<tr>
<td>GI</td>
<td>1.73 (0.28-10.59)</td>
<td>0.56</td>
</tr>
<tr>
<td>Liver</td>
<td>0.55 (0.09-3.28)</td>
<td>0.51</td>
</tr>
<tr>
<td>Chronic GVHD</td>
<td>0.21 (0.07-0.62)</td>
<td>0.004</td>
</tr>
<tr>
<td>No</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Limited</td>
<td>0.80 (0.40-1.60)</td>
<td>0.52</td>
</tr>
<tr>
<td>Extensive</td>
<td>0.24 (0.09-0.65)</td>
<td>0.005</td>
</tr>
<tr>
<td>CD34 Cell dose</td>
<td>1.12 (0.98-1.30)</td>
<td>0.11</td>
</tr>
<tr>
<td>Conditioning Regimen</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-MA</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>MA</td>
<td>2.70 (0.77-9.47)</td>
<td>0.12</td>
</tr>
<tr>
<td>Gender Mismatch</td>
<td></td>
<td>1.31 (0.50-3.44)</td>
</tr>
<tr>
<td>D-R Sex-Match</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Female to Male</td>
<td>1.36 (0.68-2.74)</td>
<td>0.39</td>
</tr>
<tr>
<td>Male to Female</td>
<td>0.79 (0.37-1.68)</td>
<td>0.54</td>
</tr>
<tr>
<td>HLA Matching</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sibling</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>Match other relative</td>
<td>N/A</td>
<td>2.90 (0.52-16.18)</td>
</tr>
<tr>
<td>Mismatch relative</td>
<td>12.39 (1.10-140.32)</td>
<td>0.04</td>
</tr>
<tr>
<td>ANC recovery</td>
<td>1.02 (0.90-1.16)</td>
<td>0.71</td>
</tr>
<tr>
<td>Plt recovery</td>
<td>0.97 (0.92-10.3)</td>
<td>0.38</td>
</tr>
</tbody>
</table>

Multivariate analysis of NRM revealed no difference among ABO incompatibility groups. Donor’s age weakly increased NRM rate (RR: 1.024, CI: 1.005-1.044, p-value=0.02). Acute GI, GVHD and cGVHD were risk factors for increasing NRM rate (RR: 3.32, CI: 1.84-6.00, p-value<0.0001 and RR: 2.26, CI: 1.11-4.60, p-value=0.02, respectively). While extensive cGVHD significantly increased NRM (RR: 2.49, CI: 1.31-4.72, p-value=0.005), limited cGVHD decreased that rate, but it was not significant (RR: 0.40, CI: 0.16-1.01, p-value=0.05) (Table 4, Figure 1-D).
Multivariate analysis of acute and chronic GVHD showed that MA regimen increased aGVHD (RR: 1.81, CI: 1.003-3.27, p-value=0.049). Omitting ATG (Antithymocyte) from conditioning regimen increased cGVHD (RR: 2.28, CI: 1.35-3.83, p-value=0.002). Both donor’s age and aGVHD grade≥II were risk factors for cGVHD (RR: 1.014, CI: 1.001-1.027, p-value=0.04 and RR: 1.49, CI: 1.02-2.20, p-value=0.04) and also female to male donation increased cGVHD (RR: 2.01, CI: 1.28-3.16, p-value=0.002).

Pure red cell aplasia (PRCA) occurred in two male patients (with ALL and SAA) in major mismatched group; one of whom had received cells from female and the other from male HLA - identical sibling donor. They received MA and non-MA regimen as conditioning, respectively. aGVHD of liver (grade II-III) and also cGVHD were presented in both patients.

**DISCUSSION**

Approximately one-third of bone marrow or peripheral blood stem cell transplantations are performed with ABO blood group incompatibility. In this study, we evaluated the impact of ABO mismatch on outcomes such as OS, RFS, and NRM, time to engraftment, relapse and also GVHD. A decrease in OS was only observed in patients undergoing minor blood group mismatched HCT.

We observed that a decrease in OS occurred only in patients with minor blood group mismatched transplantations. RFS was lower in minor mismatched grafts, but the difference was not statistically significant. Similar to our results, Ozkurt et al.’s and Logan et al.’s studies also reported a significantly shorter OS in recipients with minor ABO-mismatched grafts. Stussi et al. observed an independent decrease in survival after bidirectional ABO-incompatible SCT, but it was not found in the minor or major ABO-incompatible groups. Three hundred thirty-eight patients with ABO-incompatible SCT were evaluated by Mielcarek et al., and there were no significant differences in survival and GVHD among the ABO-incompatible groups. Some other studies have also reported no relationship between ABO groups and OS. In a large retrospective study conducted in Japan, OS was significantly lower in major and minor mismatched groups than the ABO-identical group. Time to ANC engraftment was not different among study groups. This result was confirmed in Mielcarek et al.’s and Kim et al.’s studies. We observed significant difference in mean platelet engraftment time among four groups and major mismatched group showed the maximum platelet engraftment time. Japanese study showed engraftment delay in neutrophils, platelets, and erythrocytes in transplants with major incompatibility.

Minor and bidirectional mismatched groups required more packed cell infusion than matched group. Major mismatches received more platelet infusion than others. Although Ozkurt et al. and Kim et al. studies have shown that ABO-mismatched groups had no greater transfusion requirements than ABO-identical ones, some other studies have shown that ABO-incompatible group has greater transfusion requirements. Similar to Seebach et al. study, we observed no difference in relapse and NRM between ABO-pairs. But Kimura et al. showed higher NRM in the major and minor mismatched groups. Meanwhile, just like our results, they did not find any significant difference in rate of relapse. In 2015, Biology of Blood and Marrow Transplantation Journal published an article reporting an increase in NRM of minor mismatched groups. Some studies that ABO incompatibility may be associated with increased risk of GVHD. In one report, minor ABO incompatibility was related with a higher risk of severe acute GVHD in comparison to other groups, but in our study, aGVHD and cGVHD were not statistically correlated with ABO compatibility. Mielcarek et al. and also Kim et al. have also reported similar results. Pure red cell aplasia (PRCA) occurred in two male patients (with ALL and SAA) of our major mismatched group. They received transplantation from female and male HLA - identical sibling donors, respectively. PRCA has also been reported after major ABO-incompatible stem cell transplantation in other studies. Finally, in our study, multivariate analysis revealed that MA regimen increased aGVHD and omitting ATG,
donor's age, ABO incompatibility and female to male donation were all risk factors for developing cGVHD. Since unfavorable outcomes and complications such as decrease in OS, the need for more transfusion and PRCA are statistically significant in ABO incompatible SCT, we suggest that in clinical practice, if a given patient has several suitable donors, the one with a compatible ABO blood group would improve outcomes of the transplantation. Considering relatively diverse results on this topic in the literature, a study with a larger sample size and also a meta-analysis could probably help achieve more accurate results.

CONCLUSION
Since unfavorable outcomes such as decrease in OS and the need for more transfusions are statistically significant in ABO incompatible SCT and also complications such as PRCA is observed in these patients, we suggest that in clinical practice, if a given patient has several suitable donors, the one with a compatible ABO blood group would improve outcomes of the transplantation. Considering relatively diverse results on this topic in the literature, a study with a larger sample size and also a meta-analysis could probably help achieve more accurate results.

ACKNOWLEDGEMENT
The authors would like to thank the Hematology-Oncology and Stem Cell Transplantation Research Center, Shariati Hospital.

CONFLICT OF INTEREST
The authors declare that there is no conflict of interest

REFERENCES